AusIndustry

Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Retrieved on: 
Tuesday, December 19, 2023

SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development (R&D) applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.

Key Points: 
  • SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development (R&D) applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.
  • “This development is a further endorsement of the Company’s growth potential and secures our caveat-free R&D funding long-term.”
    The Finding is one of the largest awarded in Australian history as a pillar of the R&D Tax Incentive Program administered by the Australian government.
  • This Finding does not constitute a grant or an upfront payment of the amount awarded.
  • The Australian Government extends the R&D cash rebate to the Company, capturing its local and overseas R&D activities for three years (July 1, 2022 – June 30, 2025).

Immutep receives ~A$1.13 million R&D Tax Incentive

Retrieved on: 
Wednesday, October 25, 2023

SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company’s TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Key Points: 
  • SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program.
  • Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 and TACTI-003 Australian sites were eligible for the R&D Tax Incentive.
  • Immutep also receives the French CIR tax incentive through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union.
  • Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti.

Proactive news headlines including AuKing Mining, Maximus Resources, Antilles Gold and Chase Mining Corporation

Retrieved on: 
Thursday, December 1, 2022

Click here

Key Points: 
  • Click here
    Antilles Gold Ltd (ASX:AAU, OTCQB:ANTMF) has delivered high-grade gold results including 53.5 metres at 11 g/t from 12 metres in a drill program at the outcropping gold domain of the El Pilar oxide deposit in central Cuba.
  • Click here
    Chase Mining Corporation Ltd (ASX:CML) shares rose after receiving an update from Green Critical Minerals Pty Ltd (GCM) on the Threadfin prospect within the McIntosh Graphite Project in Western Australia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Immutep Receives Australian R&D Tax Incentive

Retrieved on: 
Monday, November 14, 2022

SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2021 fiscal year, mainly related to the Company’s TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Key Points: 
  • SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Governments R&D tax incentive program.
  • Due to the Advance Finding, both Immuteps Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive.
  • As previously announced, in September 2022, Immutep also received the French CIR tax incentive of 1,804,341 (~ US$1,862,143) through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union during the 2021 calendar year.
  • Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti.

Proactive news headlines including Artrya Ltd, Horizon Minerals, International Graphite and Riversgold Ltd

Retrieved on: 
Thursday, October 27, 2022

Click here

Key Points: 
  • Click here
    Horizon Minerals Ltd (ASX:HRZ) has boosted the funds raised in its share purchase plan (SPP) to $668,391 after closing a shortfall offer.
  • Click here
    Animoca Brands Corporation Ltds subsidiary Grease Monkey Games has dropped its first-ever Nissan utility NFTs for motorsport game Torque Drift 2.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including Westar Resources, Race Oncology, Cobalt Blue Holdings and Medibank Private

Retrieved on: 
Monday, October 17, 2022

Click here

Key Points: 
  • Click here
    Cobalt Blue Holdings Ltd (ASX:COB, OTC:CBBHF) is making positive progress with processing ore from the Broken Hill Cobalt Project (BHCP) into concentrate for use in its Demonstration Plant to provide bulk samples for potential commercial partners of high-value cobalt products.
  • Click here
    Medibank Private Ltd (ASX:MPL) has resumed trading after its shares were placed in a trading halt following a cyber incident that occurred on its networks last Wednesday.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

SpineThera Awarded $5 Million Grant from Department of Defense

Retrieved on: 
Tuesday, April 26, 2022

SpineThera, Inc. , a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that the Department of Defense has awarded the company a grant for $4.97 million that will support development of SX600.

Key Points: 
  • SpineThera, Inc. , a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that the Department of Defense has awarded the company a grant for $4.97 million that will support development of SX600.
  • The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities.
  • Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
  • In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture.

Immutep receives A$1,437,826 R&D Tax Incentive

Retrieved on: 
Monday, June 22, 2020

SYDNEY, Australia, June 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Governments R&D tax incentive program.

Key Points: 
  • SYDNEY, Australia, June 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Governments R&D tax incentive program.
  • This follows approval from AusIndustry of Immuteps application for an Advance/Overseas Finding.
  • Due to the Advance Finding, both Immuteps Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive for a period of three years to 30 June 2021.
  • Immutep will apply the funding towards furthering its current active clinical trial programs for its lead product, eftilagimod alpha.